STOCK TITAN

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) - CYTO STOCK NEWS

Welcome to our dedicated page for Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) stock.

Altamira Therapeutics Ltd., formerly known as Auris Medical, is a pioneering company dedicated to developing therapeutics that address significant unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland, Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.

Altamira is actively engaged in three primary areas:

  • RNA Therapeutics: Utilizing innovative platforms such as OligoPhore™ and SemaPhore™, the company focuses on developing RNA-based therapies targeting extrahepatic sites. These platforms, currently in the preclinical stage, leverage proprietary peptides to form nanoparticles capable of delivering therapeutic RNA to tissues affected by conditions like solid tumors and inflammation.
  • Nasal Sprays: The commercially available Bentrio™ nasal spray offers protection against airborne viruses and allergens, while AM-125, which is in Phase 2 clinical trials, targets the treatment of vertigo.
  • Inner Ear Disorders: Altamira is progressing with Phase 3 development of Keyzilen® and Sonsuvi® for the intratympanic treatment of tinnitus and hearing loss, respectively.

Altamira Therapeutics is committed to advancing its pipeline through rigorous research and strategic collaborations. Recently, the company has made significant strides with its RNA therapies, as highlighted in studies such as Huang et al. (2021) and Strand et al. (2019), demonstrating the potential of targeting KRAS mutations in cancer. Moreover, ongoing research in peptide-based nanoparticles and NF-κB subunit targeting shows promising applications in inflammatory diseases and cancer treatment.

In the field of nasal sprays, Altamira's Bentrio™ has shown efficacy in clinical trials, with recent studies like Becker et al. (2024) validating its use in protecting against seasonal allergic rhinitis.

Financially, Altamira Therapeutics has reclassified its Bentrio business as discontinued operations, focusing its resources on advancing its core therapeutic areas. The company's investor communications emphasize its forward-looking strategy and commitment to innovation.

Stay updated with the latest news and developments from Altamira Therapeutics by visiting their official website and connecting through their social media channels.

Rhea-AI Summary

Altamira Therapeutics (NASDAQ:CYTO) announced reaching its target enrollment of 136 subjects in the COVAMID clinical trial, evaluating the safety and efficacy of its Bentrio nasal spray for treating acute COVID-19. The company anticipates top-line data by Q3-22, following an interim analysis to confirm statistical assumptions. Depending on the analysis, enrollment may extend to 180 patients. A positive trial outcome could lead to label expansion for Bentrio in countries requiring supportive clinical data. Bentrio is designed to protect against airborne viruses and allergens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
covid-19
-
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced encouraging results from its Phase 2 TRAVERS trial of AM-125, an intranasal formulation of betahistine for treating acute vertigo. The trial, involving 124 patients, showed a significant improvement in balance after four weeks of treatment, with participants maintaining balance for an average of 12.5 seconds compared to 7.5 seconds for the placebo group (p=0.0242). AM-125 was well-tolerated, with 34.5% of the treatment group experiencing resolution of nystagmus. The company plans to file a US FDA IND application and is looking to advance the development of AM-125.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
-
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) received a notification from the Nasdaq Listings Qualifications Department on June 2, 2022, indicating that its share price had fallen below the $1.00 minimum requirement for 30 consecutive business days. The company has a 180-day compliance period to regain compliance, during which a closing bid price of at least $1.00 for 10 consecutive days will confirm compliance. If necessary, an additional 180 days may be granted under specific conditions, including a potential reverse stock split.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
none
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced positive results from tests on Bentrio™, a drug-free nasal spray, demonstrating significant protective effects against human rhinovirus (HRV). The study showed an 89.5% reduction in viral load after preventive treatment and 98.9% after mitigative treatment compared to saline controls on Day 4. Bentrio is designed to form a protective gel in the nasal mucosa, reducing infection risk and alleviating allergic symptoms. The company anticipates further distribution in Europe and pending FDA approval for allergic rhinitis treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that its product Bentrio has received approval from Indonesia's Ministry of Health for commercialization. Bentrio is a drug-free nasal spray aimed at providing protection against airborne allergens and viruses. The product will be marketed through Wellesta Holdings Pte Ltd, covering a broad Territory including India and Southeast Asia. This approval adds to Bentrio's existing clearances in Singapore, Malaysia, and the Philippines, expanding its market reach in a country with approximately 277 million people.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ: CYTO) announced that the Philippines' FDA has approved Bentrio, its nasal spray, for commercialization in the country. Bentrio offers protection against airborne allergens and viruses and will be distributed by Wellesta Holdings across various Asian countries. Positive data from recent clinical trials indicate Bentrio's efficacy against house dust mites, a common cause of allergies. This expansion into the Philippines presents a significant market opportunity, targeting a population of 115 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Rhea-AI Summary

Altamira Therapeutics (NASDAQ:CYTO) announced positive results from its clinical trial of Bentrio nasal spray for house dust mite (HDM) allergic rhinitis. The study, involving 37 patients, showed a statistically significant reduction in nasal symptoms compared to untreated controls, with a decrease in the Total Nasal Symptom Score (TNSS) by 1.1 points (p<0.01). Bentrio, a drug-free product, demonstrated good tolerability, with over 85% of participants rating it positively. The company aims to continue the commercial roll-out of Bentrio as an effective over-the-counter treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
-
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. CEO Thomas Meyer will discuss the company's transition to RNA therapeutics and its ongoing projects, including the Bentrio nasal spray, which recently gained regulatory approval in North Macedonia for use in COVID-19 trials. The presentation is scheduled for May 24, 2022, at 7:00 AM ET. Altamira focuses on therapies for unmet medical needs in areas like RNA therapeutics and treatments for hearing loss.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
conferences
-
Rhea-AI Summary

Altamira Therapeutics (NASDAQ: CYTO) outlined its recent progress and future outlook in a shareholder letter dated May 18, 2022. The company is transitioning to a pure-play RNA therapeutics business targeting a $50 billion total addressable market (TAM). Key highlights include advancements in their RNA AM-401 program for KRAS-driven cancers, ongoing clinical trials for their nasal spray Bentrio, and upcoming data from the AM-125 nasal spray for vertigo. The plan includes divesting non-RNA legacy assets by year-end 2022 to fully focus on RNA developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
none
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced regulatory approval to extend its COVAMID clinical trial for Bentrio nasal spray into North Macedonia. This trial aims to assess the spray's efficacy in reducing SARS-CoV-2 viral load and alleviating COVID-19 symptoms. The study will involve 136 confirmed COVID-19 patients and aims for completion in 3Q-2022, depending on COVID-19 case incidence. The expansion into North Macedonia aims to enhance recruitment efforts for this important clinical investigation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
covid-19

FAQ

What is the current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?

The current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO) is $0.496 as of November 1, 2024.

What is the market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?

The market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO) is approximately 1.9M.

What areas of therapeutics does Altamira Therapeutics focus on?

Altamira Therapeutics focuses on RNA therapeutics, nasal sprays for protection against airborne viruses and allergens, and treatments for inner ear disorders.

What are the main products of Altamira Therapeutics?

Main products include the Bentrio™ nasal spray for virus and allergen protection, AM-125 for vertigo treatment, and RNA-based therapies using the OligoPhore™ and SemaPhore™ platforms.

Where is Altamira Therapeutics headquartered?

Altamira Therapeutics is headquartered in Hamilton, Bermuda, with key operations in Basel, Switzerland.

What is the stock symbol for Altamira Therapeutics?

Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.

What recent achievements has Altamira Therapeutics made in RNA therapeutics?

Altamira has made significant progress in RNA therapeutics, with studies demonstrating the potential of targeting KRAS mutations in cancer and using peptide-based nanoparticles for drug delivery.

What stage are the inner ear disorder treatments in?

Keyzilen® and Sonsuvi®, targeting tinnitus and hearing loss respectively, are currently in Phase 3 clinical development.

How does the OligoPhore™ platform work?

The OligoPhore™ platform complex therapeutic RNAs with proprietary peptides to form nanoparticles, enabling systemic delivery to tissues affected by leaky vasculature, such as in tumors and inflammatory conditions.

What are the recent clinical trial results for Bentrio™?

Recent studies, including those by Becker et al. (2024), have shown that Bentrio™ is effective in protecting against seasonal allergic rhinitis.

What is the significance of recent financial reclassifications for Altamira?

Altamira has reclassified its Bentrio business as discontinued operations to better focus resources on advancing its core therapeutic areas.

How can investors stay updated with Altamira Therapeutics?

Investors can stay updated by visiting Altamira's official website, following their social media channels, and subscribing to their official communications.

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)

Nasdaq:CYTO

CYTO Rankings

CYTO Stock Data

1.88M
3.78M
0.53%
0.13%
0.31%
Biotechnology
Healthcare
Link
United States of America
Hamilton